Edison Investment Research Limited
Edison Investment Research Limited: Edison issues update on Targovax (TRVX)
22-Jun-2020 / 17:42 GMT/BST
London, UK, 22 June 2020
Edison issues update on Targovax (TRVX)
On 22 June 2020 Targovax reported data from its Phase I/II study in
unresectable mesothelioma (a follow up to the first data published in
January 2020). There were no new safety issues and the efficacy signals seen
in the first set of data were confirmed. Importantly, the immune and gene
sequencing data provided strong support for ONCOS-102's ability to activate
the immune system and remodel the tumour microenvironment. Targovax
reiterated its plans to explore ONCOS-102 in triple combination with a
checkpoint inhibitor (CPI) and standard chemotherapy in first line. These
plans are still at a preliminary stage, but there is potential for the study
to become a registrational programme due to a high unmet need in
mesothelioma. We increase the probability of success for ONCOS-102 and our
updated valuation is NOK1.64bn or NOK21.6/share.
Our valuation has increased to NOK1.64bn or NOK21.6/share from NOK1.52bn or
NOK20.0/share after increasing the success probability in our mesothelioma
project to 25% from 20% and rolling the model forward. An update on the
upcoming Phase I melanoma trial is the key potential catalyst this year.
Click here [1] to view the full report.
All reports published by Edison are available to download free of charge
from its website
www.edisongroup.com [2]
About Edison: Edison is an investment research and advisory company, with
offices in North America, Europe, the Middle East and AsiaPac. The heart of
Edison is our world-renowned equity research platform and deep multi-sector
expertise. At Edison Investment Research, our research is widely read by
international investors, advisers and stakeholders. Edison Advisors
leverages our core research platform to provide differentiated services
including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority [3].
Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any
securities.
For more information please contact Edison:
Jonas Peciulis, +44 (0)20 3077 5728
healthcare@edisongroup.com
Learn more at www.edisongroup.com [2] and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research [4]
Twitter www.twitter.com/Edison_Inv_Res [5]
YouTube www.youtube.com/edisonitv [6]
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1076019 22-Jun-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=274a15f34b954b17a02f019f946b1aff&application_id=1076019&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=2c8688bb51e26c2c1bfa0215e9f566ad&application_id=1076019&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=1076019&site_id=vwd&application_name=news
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=edc5483da45ef361071849742dbf1595&application_id=1076019&site_id=vwd&application_name=news
5: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=1076019&site_id=vwd&application_name=news
6: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=1076019&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 22, 2020 12:42 ET (16:42 GMT)
© 2020 Dow Jones News
